BioCentury
ARTICLE | Clinical News

Elagolix: Phase III started

February 15, 2016 8:00 AM UTC

AbbVie began double-blind, placebo-controlled, U.S. Phase III trial to evaluate oral elagolix with or without estradiol/norethindrone acetate in about 400 patients. The trial includes a 6-month extens...